Literature DB >> 20053992

Sucrose octasulfate selectively accelerates thrombin inactivation by heparin cofactor II.

Suryakala Sarilla1, Sally Y Habib, Dmitri V Kravtsov, Anton Matafonov, David Gailani, Ingrid M Verhamme.   

Abstract

Inactivation of thrombin (T) by the serpins heparin cofactor II (HCII) and antithrombin (AT) is accelerated by a heparin template between the serpin and thrombin exosite II. Unlike AT, HCII also uses an allosteric interaction of its NH(2)-terminal segment with exosite I. Sucrose octasulfate (SOS) accelerated thrombin inactivation by HCII but not AT by 2000-fold. SOS bound to two sites on thrombin, with dissociation constants (K(D)) of 10 +/- 4 microm and 400 +/- 300 microm that were not kinetically resolvable, as evidenced by single hyperbolic SOS concentration dependences of the inactivation rate (k(obs)). SOS bound HCII with K(D) 1.45 +/- 0.30 mm, and this binding was tightened in the T.SOS.HCII complex, characterized by K(complex) of approximately 0.20 microm. Inactivation data were incompatible with a model solely depending on HCII.SOS but fit an equilibrium linkage model employing T.SOS binding in the pathway to higher order complex formation. Hirudin-(54-65)(SO(3)(-)) caused a hyperbolic decrease of the inactivation rates, suggesting partial competitive binding of hirudin-(54-65)(SO(3)(-)) and HCII to exosite I. Meizothrombin(des-fragment 1), binding SOS with K(D) = 1600 +/- 300 microm, and thrombin were inactivated at comparable rates, and an exosite II aptamer had no effect on the inactivation, suggesting limited exosite II involvement. SOS accelerated inactivation of meizothrombin 1000-fold, reflecting the contribution of direct exosite I interaction with HCII. Thrombin generation in plasma was suppressed by SOS, both in HCII-dependent and -independent processes. The ex vivo HCII-dependent process may utilize the proposed model and suggests a potential for oversulfated disaccharides in controlling HCII-regulated thrombin generation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20053992      PMCID: PMC2832979          DOI: 10.1074/jbc.M109.005967

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  80 in total

1.  Antithrombin activity of fucoidan. The interaction of fucoidan with heparin cofactor II, antithrombin III, and thrombin.

Authors:  F C Church; J B Meade; R E Treanor; H C Whinna
Journal:  J Biol Chem       Date:  1989-02-25       Impact factor: 5.157

2.  Transient kinetics of heparin-catalyzed protease inactivation by antithrombin III. Linkage of protease-inhibitor-heparin interactions in the reaction with thrombin.

Authors:  S T Olson
Journal:  J Biol Chem       Date:  1988-02-05       Impact factor: 5.157

3.  Transient kinetics of heparin-catalyzed protease inactivation by antithrombin III. Characterization of assembly, product formation, and heparin dissociation steps in the factor Xa reaction.

Authors:  P A Craig; S T Olson; J D Shore
Journal:  J Biol Chem       Date:  1989-04-05       Impact factor: 5.157

4.  Transient kinetics of heparin-catalyzed protease inactivation by antithrombin III. The reaction step limiting heparin turnover in thrombin neutralization.

Authors:  S T Olson; J D Shore
Journal:  J Biol Chem       Date:  1986-10-05       Impact factor: 5.157

Review 5.  Assay of coagulation proteases using peptide chromogenic and fluorogenic substrates.

Authors:  R Lottenberg; U Christensen; C M Jackson; P L Coleman
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

6.  Role of ternary complexes, in which heparin binds both antithrombin and proteinase, in the acceleration of the reactions between antithrombin and thrombin or factor Xa.

Authors:  A Danielsson; E Raub; U Lindahl; I Björk
Journal:  J Biol Chem       Date:  1986-11-25       Impact factor: 5.157

7.  Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: implications for heparin efficacy.

Authors:  P J Hogg; C M Jackson
Journal:  Proc Natl Acad Sci U S A       Date:  1989-05       Impact factor: 11.205

8.  Activation of heparin cofactor II by dermatan sulfate.

Authors:  D M Tollefsen; C A Pestka; W J Monafo
Journal:  J Biol Chem       Date:  1983-06-10       Impact factor: 5.157

9.  Structure-function relationships in heparin cofactor II: spectral analysis of aromatic residues and absence of a role for sulfhydryl groups in thrombin inhibition.

Authors:  F C Church; J B Meade; C W Pratt
Journal:  Arch Biochem Biophys       Date:  1987-12       Impact factor: 4.013

10.  Antithrombin activity of a peptide corresponding to residues 54-75 of heparin cofactor II.

Authors:  G L Hortin; D M Tollefsen; B M Benutto
Journal:  J Biol Chem       Date:  1989-08-25       Impact factor: 5.157

View more
  3 in total

1.  Glycosaminoglycan-binding properties and kinetic characterization of human heparin cofactor II expressed in Escherichia coli.

Authors:  Suryakala Sarilla; Sally Y Habib; Douglas M Tollefsen; David B Friedman; Diana R Arnett; Ingrid M Verhamme
Journal:  Anal Biochem       Date:  2010-07-27       Impact factor: 3.365

2.  Interaction of thrombin with sucrose octasulfate.

Authors:  Bijoy J Desai; Rio S Boothello; Akul Y Mehta; J Neel Scarsdale; H Tonie Wright; Umesh R Desai
Journal:  Biochemistry       Date:  2011-07-18       Impact factor: 3.162

3.  Fluorescent reporters of thrombin, heparin cofactor II, and heparin binding in a ternary complex.

Authors:  Ingrid M Verhamme
Journal:  Anal Biochem       Date:  2011-12-06       Impact factor: 3.365

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.